Phase I trials with anti-PD-1 or anti-PD-L1 have shown response rates of 18–28% and 10–17%, respectively, in patients with melanoma, NSCLC, and renal carcinoma [8]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.